Vivpro Corp’s Post

Will Pharma Survive This Shakeup? Trump’s bold appointments, including Elon Musk and RFK Jr., are rewriting the playbook for clinical trials and drug marketing. What does this mean for the industry? Click below to find out. #trumpadministration #healthcarereform #pharmainnovation #kulkarnilawfirm #klf 

Ready for Pharma Chaos? Musk, RFK Jr., and other controversial picks are shaking up the life sciences industry. Are clinical trials and drug advertising about to face major changes? Link in comments. #trumpteam #lifesciences #clinicalresearch #drugadvertising #kulkarnilawfirm #klf 

At CRIO, we're all about making a big impact in our industry. That's why we've been jumping into the FDA's public comment process on different draft guidelines. Most recently, we shared our thoughts on the FDA's draft guidance for Diversity Action Plans. With 136 comments from Pharma, CROs, industry groups, and other stakeholders, it's clear this is a hot topic! Read our comments here and below: https://lnkd.in/ehb8yrrn #FDA #DiversityActionPlans #eSource #Diversity #clinicaltrials Hannah Kulkarni

While we aren't heading to #BIO2024 in San Diego next week, we'll be there for those of you sticking around until #DIAAnnual! Safe travels everyone, and don't forget to meet us during #DIA2024. We'll be debuting our latest #regulatory, #clinical, and #quality features at Booth #1508. Have a good weekend everyone! DRUG INFORMATION ASSOCIATION (DIA) #lifesciences #pharma #drugdevelopment #drugdiscovery #clinicaltrials #clinicalresearch #regulatoryaffairs #regops #clinicaloperations

Biomedtracker and Evaluate Ltd Pharma are available via Snowflake. Access real-time tracking and analysis of the drug development pipeline and navigate the complex commercial, clinical, and regulatory landscape with precision: https://ow.ly/NcZ250ThuSQ.

Biomedtracker and Evaluate Ltd Pharma are available via Snowflake. Access real-time tracking and analysis of the drug development pipeline and navigate the complex commercial, clinical, and regulatory landscape with precision: https://ow.ly/24WV50Thu6u

Free Webinar Alert! ** What Sponsors need to know about the latest FDA Diversity plan guidance** Join Beatriz Rocha & Teresa Oblak from Fortrea on Nov 14th (10am EST) as they break down the latest FDA guidance on diversity in clinical trials. What you'll learn: • Key changes & impact on your work • Case studies & real-world examples • Future trends & how to prepare Perfect for: Pharma & Biotech professionals Register for FREE (TOPRA membership included!) https://lnkd.in/eWYb4t_R #Diversity #ClinicalTrials #webinar

Biomedtracker and Evaluate Ltd Pharma are available via Snowflake. Access real-time tracking and analysis of the drug development pipeline and navigate the complex commercial, clinical, and regulatory landscape with precision: https://ow.ly/tqgS50ThuRw.

Delays caused by regulatory hurdles are preventing patients from accessing drugs that could save their lives. It is critical that biopharma and diagnostic providers have the necessary tools to navigate the regulatory requirements and accelerate approvals. Covering everything from LDT updates, IVDR, reimbursement and more, this summit is your chance to stay ahead of the curve and listen to the thought leaders who are sharply navigating confusing regulatory requirements; download the brochure below to see this comprehensive agenda, where you can learn from the leaders, collaborate, and improve your regulatory strategies: https://ter.li/3ahhpw This is free to attend (see t&c) for academics and drug developers. For service providers in the space - you can save over $200 if you register before this Friday (17th)! Here is a sneak peak at some of our top industry leaders: Jai Pandey, PhD, Vihanga Pahalawatta, Lori Roadcap, Andrea Renninger, Claudia Dollins, Mary J. Savage, Deb Rasmussen, Ralph Riley, Dun Liang, Andrew L'Huillier, Sid Mathur, Qing Li, MD. PhD, Kaska (Katarzyna) Kowanetz, PhD, RAC, Brian Baker and more Download the brochure here: https://ter.li/3ahhpw

While diversity has been an important topic in the clinical trial industry for many years, new guidance from the FDA has put the focus on action for 2025 and beyond. Learn more in this article from PCM TRIALS - Quality Mobile Research #pharma #clinicaltrials #trialdiversity #mobilenursing